A Phase 4 interventional study of Atorvastatin 10 mg and Placebo in Hypertensive Disorders of Pregnancy, Preeclampsia and Gestational Hypertension, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Ohio State University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pre-Eclampsia by Ohio State University — 4 open to participants now, 4 under way, none of them phase 3. Pre-Eclampsia · Ohio State University.
Among the 11 studies in Pre-Eclampsia by Ohio State University, this one is the only one that started in 2025, is one of 5 in phase 4, and was the 10th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →4 of the 11 studies in Pre-Eclampsia by Ohio State University are open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 14–35 · Women only
Ohio State University · Sites in United States
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 20 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 131 across the 6 interventional studies, 61 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
1 of the studies in Pre-Eclampsia by Ohio State University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06632379Ohio State UniversityAtorvaStatin Postpartum and Reduction of Cardiovascular risK | 2027-09-15 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Pre-Eclampsia by Ohio State University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
Individuals will be followed for up to 1 year to address the following specific aims:
Specific Aim 1: To determine if among individuals diagnosed with hypertensive disorders of pregnancy (HDP), the use of atorvastatin 10 mg daily initiated in the postpartum period following cessation of breastfeeding and continued for 3 months, lowers cardiovascular risk, as measured by the Framingham Risk Score for Cardiovascular Disease (30 year risk, primary outcome) and cardiovascular risk prediction model (PREVENT, secondary outcome) compared with placebo; and if the benefit will persist for at least 3-6 months following discontinuation of atorvastatin treatment.
Specific Aim 2: To determine if among individuals diagnosed with HDP the use of atorvastatin 10 mg daily initiated in the postpartum period following cessation of breastfeeding and continued for 3 months lowers the frequency of metabolic syndrome, improves lipid levels, and reduces inflammatory markers compared with placebo; and if this benefit will persist for at least 3-6 months following discontinuation of atorvastatin treatment.
Specific Aim 3: Determine if circulating extracellular vesicles (EVs) from patients with HDP mediate increased CV risk factors and the potential of EV-based therapeutics to dampen these risk factors. We will isolate plasma-derived EVs from individuals with HDP using retrospective samples and perform in vivo and in vitro functional and metabolic assays. We will also analyze the molecular cargo of EVs isolated from individuals in Aim 1 to identify specific pathways that can be targeted via engineered EVs to attenuate the increased CV risk after HDP.
The criteria were revised on the registry on Oct 23, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atorvastatin 10 mg daily for 3 months
Drug: Atorvastatin 10 mg
Identical appearing placebo for 3 months
Drug: Placebo
Participants will be assigned to 10 mg Atorvastatin
Participants will be assigned to identical appearing placebo
The 30-year Framingham Risk Score for Cardiovascular Disease
Predicts 0-100% risk of "hard" CVD events (coronary death, myocardial infarction, stroke) based on sex, systolic blood pressure, antihypertensive treatment, total and high-density lipoprotein cholesterol, smoking, and diabetes mellitus. A higher number reflects a greater risk of adverse CVD events, whereas a lower number reflects lower risk.
Time frame: After 3 months of study treatment, up to 9 months after enrollment
Drug Use and Side Effects
Individuals will be contacted monthly via phone call to assess drug tolerability and use using a survey, which reviews any adverse events or concerns related to use of the study drug.
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Framingham Risk Score for Cardiovascular Disease 3-6 months following medication cessation
Enrolled individuals will be contacted via telephone at 3-6 months after they complete medication use and will be invited to a visit for a Framingham Risk Score calculation. The Framingham Risk Score predicts 0-100% risk of CVD events, with a higher number reflecting a greater risk of adverse CVD events, whereas a lower number reflects lower risk.
Time frame: Anytime after 3-6 months of stopping to use the study drug, up to 9 months from randomization
PREVENT (AHA Predicting Risk of CVD Events) score
A glomerular filtration rate will be calculated for each enrolled individual upon enrollment and at the additional biospecimen visits in order to enable calculation of the PREVENT score.
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Rates of primary care provider (PCP) visits within 9-12 months of delivery
Enrolled individuals will undergo a telephone survey at 9-12 months postpartum, assessing whether they have attended a visit with a primary care provider (internal medicine, family medicine or primary care nurse practitioner), and for what reason, since the time of their delivery
Time frame: From randomization until 6 months after stopping to use the study drug, up to 12 months from delivery
Waist circumference
Waist circumference in centimeters will be measured at the study visits to help identify those with metabolic syndrome (circumference of 88 cm or more).
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Fasting glucose
Fasting glucose levels will be measured at the study visits to help identify those with metabolic syndrome (fasting glucose above or equal to 100 mg/dL).
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Number of individuals diagnosed with metabolic syndrome
The presence of metabolic syndrome will be defined as 3 or more of the following, which are also listed as individual outcomes: waist circumference greater or equal to 88 cm, triglycerides greater or equal to 150 mg/dL, HDL cholesterol \<50 mg/dL, blood pressure greater or equal to 130/85, and fasting glucose greater or equal to 100 mg/dL.
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Lipid levels
Serum testing for total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Hypertension diagnosis & need for antihypertensive therapy
Blood pressure will be measured at the study visits to identify new development of hypertension; enrolled individuals will be asked if they have started medication for hypertension
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Diabetes diagnosis & need for anti-glycemic therapy
Hemoglobin A1C will be measured at the study visits to identify new development of diabetes mellitus (HbA1C \> 6.5%) and individuals will be asked if they have started anti-glycemic medication
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Systolic blood pressure
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Estimated glomerular filtration rate
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
High-sensitivity C-reactive protein (Hs-CRP) level
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Lipoprotein (a) level
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Apolipoprotein (b) level
Time frame: From randomization until 6 months after stopping to use the study drug, up to 9 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.
Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 23 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin